CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
7.48
-0.17 (-2.22%)
At close: Apr 28, 2026, 4:00 PM EDT
7.46
-0.02 (-0.27%)
After-hours: Apr 28, 2026, 4:10 PM EDT

Company Description

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.

The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.

It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.
CVRx, Inc. logo
Country United States
Founded 2000
IPO Date Jun 30, 2021
Industry Medical Devices
Sector Healthcare
Employees 223
CEO Kevin Hykes

Contact Details

Address:
9201 West Broadway Avenue, Suite 650
Minneapolis, Minnesota 55445
United States
Phone 763 416 2840
Website cvrx.com

Stock Details

Ticker Symbol CVRX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001235912
CUSIP Number 126638105
ISIN Number US1266381052
SIC Code 3841

Key Executives

Name Position
Kevin Hykes President, Chief Executive Officer and Director
Dr. Philip B. Adamson M.D., M.Sc. Chief Medical Officer
Robert Allen John Chief Revenue Officer
Jared Oasheim Chief Financial Officer
Brent Binkowski Chief Operating Officer
Jonelle R. Burnham Vice President and General Counsel
Paul Verrastro Chief Marketing and Strategy Officer
Gregory Morrison Chief Human Resources Officer
Bonnie Handke M.B.A., R.N. Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics

Latest SEC Filings

Date Type Title
Apr 20, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 20, 2026 DEF 14A Other definitive proxy statements
Apr 13, 2026 8-K Current Report
Mar 3, 2026 8-K Current Report
Feb 13, 2026 S-8 Securities to be offered to employees in employee benefit plans
Feb 13, 2026 10-K Annual Report
Feb 12, 2026 8-K Current Report
Jan 12, 2026 SCHEDULE 13G/A Filing
Jan 12, 2026 8-K Current Report
Jan 12, 2026 424B5 Filing